Target intelligence / Profile preview

CD4+ T-cell receptor specific for carrier-derived peptide–MHC II complexes

Molecular classification
Receptor, T-cell receptor complex, Heterodimeric protein
01

Overview

CD4+ T-cell receptors (TCRs) specific for carrier-derived peptide–MHC II complexes are specialized heterodimeric proteins on the surface of helper T cells that recognize processed peptide fragments from carrier proteins (e.g., CRM197, tetanus toxoid) presented by Major Histocompatibility Complex class II (MHC II) molecules (Janeway et al., 2001). This recognition is the pivotal step in the mechanism of conjugate vaccines, where the TCR-mediated activation of CD4+ T cells provides the necessary "linked help" to B cells for the production of high-affinity antibodies against otherwise poorly immunogenic antigens like bacterial polysaccharides (Avci et al., 2011). These receptors are essential for the induction of immunological memory and the success of pediatric vaccination programs against pathogens such as Streptococcus pneumoniae and Haemophilus influenzae (Pichichero, 2013). In therapeutic development, these TCRs are targeted to optimize vaccine formulations and are being studied for their role in potential cross-reactivity or carrier-induced epitopic suppression. Their precise interaction with the peptide-MHC complex dictates the magnitude and quality of the adaptive immune response, making them a critical focus for synthetic immunology and rational vaccine design.

Other names
Carrier-specific T-cell receptorMHC II-restricted T-cell receptorCD4+ TCRAntigen-specific T-cell receptor
02

Mechanism of action

Recognition of carrier-derived peptides presented by MHC II molecules on antigen-presenting cells or B cells, triggering T-cell activation and subsequent B-cell help for antibody production (Avci et al., 2011; Pichichero, 2013).

03

Biological functions

Immune responseT-cell activationAntigen recognitionB-cell helpCytokine production
04

Disease associations

InfectionAutoimmunityCancer
05

Safety considerations

HypersensitivityCytokine release syndromeCross-reactivity with self-antigensCarrier-induced epitopic suppression
06

Interacting drugs

CRM197

4 more in the full profile.

07

Biomarkers

CD4MHC class IITCR alpha/beta chainsInterferon-gammaInterleukin-4

Beyond the preview

Go deeper on CD4+ T-cell receptor specific for carrier-derived peptide–MHC II complexes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD4+ T-cell receptor specific for carrier-derived peptide–MHC II complexes.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call